2020 Q4 Form 10-Q Financial Statement
#000135657620000076 Filed on November 06, 2020
Income Statement
Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
---|---|---|---|
Revenue | $143.6M | $155.1M | $102.1M |
YoY Change | 42.96% | 51.88% | -0.83% |
Cost Of Revenue | $18.50M | $21.39M | $4.819M |
YoY Change | 351.22% | 343.83% | 14.55% |
Gross Profit | $125.0M | $133.7M | $97.32M |
YoY Change | 29.8% | 37.43% | -1.49% |
Gross Profit Margin | 87.05% | 86.21% | 95.28% |
Selling, General & Admin | $56.20M | $54.46M | $39.34M |
YoY Change | 57.42% | 38.42% | -3.79% |
% of Gross Profit | 44.96% | 40.72% | 40.43% |
Research & Development | $17.90M | $16.84M | $16.94M |
YoY Change | -9.6% | -0.61% | -17.04% |
% of Gross Profit | 14.32% | 12.59% | 17.41% |
Depreciation & Amortization | $5.500M | $7.600M | $1.600M |
YoY Change | 223.53% | 375.0% | -15.79% |
% of Gross Profit | 4.4% | 5.68% | 1.64% |
Operating Expenses | $82.00M | $71.30M | $56.29M |
YoY Change | 47.75% | 26.67% | -8.2% |
Operating Profit | $43.00M | $56.14M | $39.73M |
YoY Change | 5.35% | 41.31% | 6.01% |
Interest Expense | $700.0K | $6.088M | $5.662M |
YoY Change | -121.21% | 7.52% | 5562.0% |
% of Operating Profit | 1.63% | 10.84% | 14.25% |
Other Income/Expense, Net | -$4.000M | -$3.429M | -$139.0K |
YoY Change | -217.65% | 2366.91% | -87.41% |
Pretax Income | $39.70M | $52.71M | $39.59M |
YoY Change | -2.93% | 33.14% | 8.85% |
Income Tax | $8.900M | $12.71M | $10.73M |
% Of Pretax Income | 22.42% | 24.12% | 27.1% |
Net Earnings | $30.80M | $40.00M | $28.86M |
YoY Change | -7.03% | 38.59% | 3.03% |
Net Earnings / Revenue | 21.45% | 25.78% | 28.26% |
Basic Earnings Per Share | $0.76 | $0.55 | |
Diluted Earnings Per Share | $572.5K | $0.74 | $0.54 |
COMMON SHARES | |||
Basic Shares Outstanding | 52.69M shares | 52.66M shares | 52.45M shares |
Diluted Shares Outstanding | 53.76M shares | 53.81M shares |
Balance Sheet
Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $422.5M | $352.0M | $296.7M |
YoY Change | 21.72% | 18.64% | 5.89% |
Cash & Equivalents | $288.6M | $204.3M | $116.9M |
Short-Term Investments | $133.9M | $147.7M | $179.8M |
Other Short-Term Assets | $18.70M | $24.50M | $18.20M |
YoY Change | 61.21% | 34.62% | 95.7% |
Inventory | $48.33M | $42.47M | $25.50M |
Prepaid Expenses | |||
Receivables | $140.9M | $133.1M | $86.70M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $630.4M | $552.0M | $427.1M |
YoY Change | 33.38% | 29.25% | 9.34% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $37.82M | $17.40M | $9.977M |
YoY Change | 121.61% | 74.35% | 44.59% |
Goodwill | $77.91M | $89.14M | |
YoY Change | |||
Intangibles | $364.3M | $402.3M | $26.10M |
YoY Change | 1366.76% | 1441.19% | |
Long-Term Investments | $350.4M | $388.2M | $596.4M |
YoY Change | -40.79% | -34.91% | 29.57% |
Other Assets | $43.25M | $18.32M | $574.0K |
YoY Change | 97.54% | 3092.33% | -98.21% |
Total Long-Term Assets | $873.7M | $958.0M | $679.8M |
YoY Change | 27.06% | 40.92% | 27.81% |
TOTAL ASSETS | |||
Total Short-Term Assets | $630.4M | $552.0M | $427.1M |
Total Long-Term Assets | $873.7M | $958.0M | $679.8M |
Total Assets | $1.504B | $1.510B | $1.107B |
YoY Change | 29.63% | 36.42% | 19.99% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $6.147M | $11.19M | $3.090M |
YoY Change | -39.38% | 262.23% | -68.47% |
Accrued Expenses | $78.93M | $197.0M | $138.9M |
YoY Change | 58.78% | 41.83% | 17.61% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $3.600M | ||
YoY Change | |||
Total Short-Term Liabilities | $245.1M | $299.6M | $149.7M |
YoY Change | 52.63% | 100.11% | 8.26% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $361.8M | $376.8M | $341.2M |
YoY Change | 4.81% | 10.43% | 4.76% |
Other Long-Term Liabilities | $42.79M | $9.304M | $11.21M |
YoY Change | 49.32% | -17.01% | -69.37% |
Total Long-Term Liabilities | $42.79M | $9.304M | $11.21M |
YoY Change | 49.32% | -17.01% | -96.91% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $245.1M | $299.6M | $149.7M |
Total Long-Term Liabilities | $42.79M | $9.304M | $11.21M |
Total Liabilities | $759.2M | $801.1M | $549.7M |
YoY Change | 34.41% | 45.75% | 9.8% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | $326.5M | $295.7M | $166.4M |
YoY Change | 63.62% | 77.7% | |
Common Stock | $53.00K | $53.00K | $52.00K |
YoY Change | 0.0% | 1.92% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $744.9M | $708.9M | $557.3M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $1.504B | $1.510B | $1.107B |
YoY Change | 29.63% | 36.42% | 19.99% |
Cashflow Statement
Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | $30.80M | $40.00M | $28.86M |
YoY Change | -7.03% | 38.59% | 3.03% |
Depreciation, Depletion And Amortization | $5.500M | $7.600M | $1.600M |
YoY Change | 223.53% | 375.0% | -15.79% |
Cash From Operating Activities | $31.90M | $5.600M | $37.60M |
YoY Change | -27.17% | -85.11% | -39.74% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$200.0K | -$100.0K | -$500.0K |
YoY Change | -90.0% | -80.0% | 400.0% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $49.50M | -$11.10M | -$7.900M |
YoY Change | 130.23% | 40.51% | -130.98% |
Cash From Investing Activities | $49.30M | -$11.30M | -$8.400M |
YoY Change | 152.82% | 34.52% | -133.2% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 3.100M | -1.000M | 300.0K |
YoY Change | 158.33% | -433.33% | -62.5% |
NET CHANGE | |||
Cash From Operating Activities | 31.90M | 5.600M | 37.60M |
Cash From Investing Activities | 49.30M | -11.30M | -8.400M |
Cash From Financing Activities | 3.100M | -1.000M | 300.0K |
Net Change In Cash | 84.30M | -6.700M | 29.50M |
YoY Change | 30.7% | -122.71% | -66.67% |
FREE CASH FLOW | |||
Cash From Operating Activities | $31.90M | $5.600M | $37.60M |
Capital Expenditures | -$200.0K | -$100.0K | -$500.0K |
Free Cash Flow | $32.10M | $5.700M | $38.10M |
YoY Change | -29.91% | -85.04% | -39.04% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001356576 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2020 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-09-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-35518 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
SUPERNUS PHARMACEUTICALS, INC. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
20-2590184 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
9715 Key West Avenue | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Rockville | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MD | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
20850 | ||
dei |
City Area Code
CityAreaCode
|
301 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
838-2500 | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.001 par value per share | ||
CY2020Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
52685121 | shares |
dei |
Trading Symbol
TradingSymbol
|
SUPN | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
204293000 | USD |
CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
181381000 | USD |
CY2020Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
147657000 | USD |
CY2019Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
165692000 | USD |
CY2020Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
133107000 | USD |
CY2019Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
87332000 | USD |
CY2020Q3 | us-gaap |
Inventory Net
InventoryNet
|
42465000 | USD |
CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
26628000 | USD |
CY2020Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
24493000 | USD |
CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
11611000 | USD |
CY2020Q3 | us-gaap |
Assets Current
AssetsCurrent
|
552015000 | USD |
CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
472644000 | USD |
CY2020Q3 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
388185000 | USD |
CY2019Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
591773000 | USD |
CY2020Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17395000 | USD |
CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17068000 | USD |
CY2020Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
21019000 | USD |
CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
21279000 | USD |
CY2020Q3 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
21676000 | USD |
CY2019Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
0 | USD |
CY2020Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
402265000 | USD |
CY2019Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
24840000 | USD |
CY2020Q3 | us-gaap |
Goodwill
Goodwill
|
89143000 | USD |
CY2019Q4 | us-gaap |
Goodwill
Goodwill
|
0 | USD |
CY2020Q3 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
0 | USD |
CY2019Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
32063000 | USD |
CY2020Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
18324000 | USD |
CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
615000 | USD |
CY2020Q3 | us-gaap |
Assets
Assets
|
1510022000 | USD |
CY2019Q4 | us-gaap |
Assets
Assets
|
1160282000 | USD |
CY2020Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
11193000 | USD |
CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
10141000 | USD |
CY2020Q3 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
136973000 | USD |
CY2019Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
107629000 | USD |
CY2020Q3 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
56289000 | USD |
CY2019Q4 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
34305000 | USD |
CY2020Q3 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
82900000 | USD |
CY2019Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
0 | USD |
CY2020Q3 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
0 | USD |
CY2019Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
2443000 | USD |
CY2020Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3741000 | USD |
CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2825000 | USD |
CY2020Q3 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
3612000 | USD |
CY2019Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
0 | USD |
CY2020Q3 | supn |
Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
|
4898000 | USD |
CY2019Q4 | supn |
Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
|
3244000 | USD |
CY2020Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
299606000 | USD |
CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
160587000 | USD |
CY2020Q3 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
357521000 | USD |
CY2019Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
345170000 | USD |
CY2020Q3 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
33000000 | USD |
CY2019Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
0 | USD |
CY2020Q3 | supn |
Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
|
14960000 | USD |
CY2019Q4 | supn |
Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
|
19248000 | USD |
CY2020Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
29522000 | USD |
CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
30440000 | USD |
CY2020Q3 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
19289000 | USD |
CY2019Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
0 | USD |
CY2020Q3 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
37941000 | USD |
CY2019Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
0 | USD |
CY2020Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
9304000 | USD |
CY2019Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
9409000 | USD |
CY2020Q3 | us-gaap |
Liabilities
Liabilities
|
801143000 | USD |
CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
564854000 | USD |
CY2020Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2020Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2020Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
52670121 | shares |
CY2020Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
52670121 | shares |
CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
52533348 | shares |
CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
52533348 | shares |
CY2020Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
53000 | USD |
CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
53000 | USD |
CY2020Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
403396000 | USD |
CY2019Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
388410000 | USD |
CY2020Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
9700000 | USD |
CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
7417000 | USD |
CY2020Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
295730000 | USD |
CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
199548000 | USD |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
708879000 | USD |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
595428000 | USD |
CY2020Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1510022000 | USD |
CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1160282000 | USD |
CY2020Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
155135000 | USD |
CY2019Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
102140000 | USD |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
376840000 | USD | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
292309000 | USD | |
CY2020Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
21388000 | USD |
CY2019Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
4819000 | USD |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
33926000 | USD | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
12547000 | USD | |
CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
16839000 | USD |
CY2019Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
16943000 | USD |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
58023000 | USD | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
49307000 | USD | |
CY2020Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
54660000 | USD |
CY2019Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
39343000 | USD |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
144377000 | USD | |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
118782000 | USD | |
CY2020Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
6108000 | USD |
CY2019Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1306000 | USD |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9814000 | USD | |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
3918000 | USD | |
CY2020Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
98995000 | USD |
CY2019Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
62411000 | USD |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
246140000 | USD | |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
184554000 | USD | |
CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
56140000 | USD |
CY2019Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
39729000 | USD |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
130700000 | USD | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
107755000 | USD | |
CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3262000 | USD |
CY2019Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
5559000 | USD |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
12988000 | USD | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
15696000 | USD | |
CY2020Q3 | us-gaap |
Interest Expense
InterestExpense
|
6088000 | USD |
CY2019Q3 | us-gaap |
Interest Expense
InterestExpense
|
5662000 | USD |
us-gaap |
Interest Expense
InterestExpense
|
17658000 | USD | |
us-gaap |
Interest Expense
InterestExpense
|
16930000 | USD | |
CY2020Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-603000 | USD |
CY2019Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-36000 | USD |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2925000 | USD | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
54000 | USD | |
CY2020Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3429000 | USD |
CY2019Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-139000 | USD |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1745000 | USD | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1180000 | USD | |
CY2020Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
52711000 | USD |
CY2019Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
39590000 | USD |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
128955000 | USD | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
106575000 | USD | |
CY2020Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
12714000 | USD |
CY2019Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
10730000 | USD |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
32773000 | USD | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
26648000 | USD | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39997000 | USD |
CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
28860000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
96182000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
79927000 | USD | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.76 | |
CY2019Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.55 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.83 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.53 | ||
CY2019Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.54 | |
CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.74 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.79 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.48 | ||
CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52658850 | shares |
CY2019Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52453384 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52583891 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52392232 | shares | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53762642 | shares |
CY2019Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53805838 | shares |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53663273 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53898486 | shares | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39997000 | USD |
CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
28860000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
96182000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
79927000 | USD | |
CY2020Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-1659000 | USD |
CY2019Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
1337000 | USD |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
2283000 | USD | |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
10419000 | USD | |
CY2020Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1659000 | USD |
CY2019Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
1337000 | USD |
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
2283000 | USD | |
us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
10419000 | USD | |
CY2020Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
38338000 | USD |
CY2019Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
30197000 | USD |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
98465000 | USD | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
90346000 | USD | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
595428000 | USD |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3988000 | USD |
CY2020Q1 | supn |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
32000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
21518000 | USD |
CY2020Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-7583000 | USD |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
613383000 | USD |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4962000 | USD |
CY2020Q2 | supn |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
1437000 | USD |
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
34667000 | USD |
CY2020Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
11525000 | USD |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
665974000 | USD |
CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4490000 | USD |
CY2020Q3 | supn |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
77000 | USD |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39997000 | USD |
CY2020Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-1659000 | USD |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
708879000 | USD |
CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
453023000 | USD |
CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3287000 | USD |
CY2019Q1 | supn |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
783000 | USD |
CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18340000 | USD |
CY2019Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
4585000 | USD |
CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
480018000 | USD |
CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4022000 | USD |
CY2019Q2 | supn |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
1640000 | USD |
CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
32727000 | USD |
CY2019Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
4497000 | USD |
CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
522904000 | USD |
CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3914000 | USD |
CY2019Q3 | supn |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
242000 | USD |
CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
28860000 | USD |
CY2019Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
1337000 | USD |
CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
557257000 | USD |
us-gaap |
Profit Loss
ProfitLoss
|
96182000 | USD | |
us-gaap |
Profit Loss
ProfitLoss
|
79927000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13440000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11223000 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
12621000 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
5029000 | USD | |
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
3217000 | USD | |
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
3058000 | USD | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
12351000 | USD | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
11701000 | USD | |
us-gaap |
Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
|
3636000 | USD | |
us-gaap |
Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
|
131000 | USD | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
200000 | USD | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | USD | |
supn |
Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
|
4515000 | USD | |
supn |
Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
|
4331000 | USD | |
supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
6320000 | USD | |
supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
5028000 | USD | |
supn |
Noncash Operating Lease Cost
NoncashOperatingLeaseCost
|
2599000 | USD | |
supn |
Noncash Operating Lease Cost
NoncashOperatingLeaseCost
|
2600000 | USD | |
us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-280000 | USD | |
us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-1689000 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
26840000 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-16344000 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
5437000 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-155000 | USD | |
supn |
Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
|
9318000 | USD | |
supn |
Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
|
4236000 | USD | |
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
2416000 | USD | |
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
141000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1527000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-334000 | USD | |
supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
21166000 | USD | |
supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
-9013000 | USD | |
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
8410000 | USD | |
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1120000 | USD | |
us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
-2538000 | USD | |
us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
-7559000 | USD | |
us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-3489000 | USD | |
us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-1903000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
106466000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
99338000 | USD | |
us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
297200000 | USD | |
us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
0 | USD | |
us-gaap |
Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
|
15000000 | USD | |
us-gaap |
Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
|
0 | USD | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
87890000 | USD | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
361121000 | USD | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
319421000 | USD | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
184467000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3234000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
707000 | USD | |
us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
141000 | USD | |
us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
1000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-84044000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-177362000 | USD | |
us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
1056000 | USD | |
us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
0 | USD | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1546000 | USD | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2665000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
490000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2665000 | USD | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
22912000 | USD | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-75359000 | USD | |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
181381000 | USD |
CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
192248000 | USD |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
204293000 | USD |
CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
116889000 | USD |
us-gaap |
Interest Paid Net
InterestPaidNet
|
2516000 | USD | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
2516000 | USD | |
us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
42284000 | USD | |
us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
35933000 | USD | |
us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
115900000 | USD | |
us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
0 | USD | |
supn |
Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
|
352000 | USD | |
supn |
Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
|
495000 | USD | |
supn |
Property And Equipment Acquired Under Build To Suit Lease Transaction
PropertyAndEquipmentAcquiredUnderBuildToSuitLeaseTransaction
|
0 | USD | |
supn |
Property And Equipment Acquired Under Build To Suit Lease Transaction
PropertyAndEquipmentAcquiredUnderBuildToSuitLeaseTransaction
|
387000 | USD | |
supn |
Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
|
25225000 | USD | |
supn |
Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
|
31856000 | USD | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
Organization and Business<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware, commencing operations in 2005. The Company is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, marketing five products, including: Oxtellar XR for the treatment of epilepsy; Trokendi XR for the prophylaxis of migraine headache and the treatment of epilepsy; APOKYN and XADAGO for the treatment of Parkinson's disease; and MYOBLOC for the treatment of cervical dystonia and sialorrhea. The Company is also developing multiple proprietary CNS product candidates to address significant unmet medical needs and market opportunities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched Oxtellar XR and Trokendi XR for the treatment of epilepsy in 2013, followed by the launch of Trokendi XR for the prophylaxis of migraine headache in adolescents and adults in 2017. The Company launched Oxtellar XR with an expanded indication, including monotherapy for partial seizures in January 2019. On June 9, 2020, the Company completed the acquisition of the CNS portfolio of US WorldMeds Partners, LLC (USWM Acquisition). With the acquisition, the Company acquired the right to further develop and commercialize three marketed products, as well as a product candidate in late-stage development. Refer to Note 3 for further discussion on the USWM Acquisition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations, and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of September 30, 2020. Through the first nine months of 2020, the pandemic has had limited effect on the Company's business operations, and no material impact on its condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.</span></div> | ||
supn |
Number Of Proprietary Commercial Products
NumberOfProprietaryCommercialProducts
|
5 | marketProduct | |
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment | |
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reclassifications</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts in the condensed consolidated statements of earnings have been reclassified to conform to the current year presentation, including a reclassification made to separately present amortization of intangible assets. This was previously included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and now is recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statements of earnings. These reclassifications had no effect on operating earnings or on our other condensed consolidated financial statements for the three and nine months ended September 30, 2020 and 2019.</span></div> | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div> | ||
supn |
Sales Return Period Prior To Expiration
SalesReturnPeriodPriorToExpiration
|
P6M | ||
supn |
Sales Return Period
SalesReturnPeriod
|
P12M | ||
supn |
Number Of Proprietary Commercial Products
NumberOfProprietaryCommercialProducts
|
5 | product | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P10Y | ||
supn |
Business Acquisition Transaction Costs Adjustment
BusinessAcquisitionTransactionCostsAdjustment
|
10100000 | USD | |
CY2020Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
155135000 | USD |
CY2019Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
102140000 | USD |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
376840000 | USD | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
292309000 | USD | |
CY2020Q3 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
2400000 | USD |
supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
6300000 | USD | |
CY2019Q3 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
1600000 | USD |
supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
5000000.0 | USD | |
CY2020Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
522920000 | USD |
CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
747598000 | USD |
CY2020Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
13835000 | USD |
CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
10031000 | USD |
CY2020Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
913000 | USD |
CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
164000 | USD |
CY2020Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
535842000 | USD |
CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
757465000 | USD |
CY2020Q3 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
147657000 | USD |
CY2020Q3 | supn |
Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
|
142272000 | USD |
CY2020Q3 | supn |
Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue
|
136095000 | USD |
CY2020Q3 | supn |
Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue
|
109818000 | USD |
CY2020Q3 | supn |
Available For Sale Securities Debt Maturities Thereafter Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue
|
0 | USD |
CY2020Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
535842000 | USD |
us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
|
0 | USD | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11223000 | USD | |
CY2020Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.9063 | |
CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4490000 | USD |
CY2019Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3914000 | USD |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13440000 | USD | |
CY2020Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.9063 | |
CY2020Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.9063 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
39997000 | USD |
CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
28860000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
96182000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
79927000 | USD | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52658850 | shares |
CY2019Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52453384 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52583891 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52392232 | shares | |
CY2020Q3 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1103792 | shares |
CY2019Q3 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1352454 | shares |
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1079382 | shares | |
us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1506254 | shares | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53762642 | shares |
CY2019Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53805838 | shares |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53663273 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53898486 | shares | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.76 | |
CY2019Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.55 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.83 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
1.53 | ||
CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.74 | |
CY2019Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.54 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.79 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
1.48 | ||
CY2020Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
12714000 | USD |
CY2019Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
10730000 | USD |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
32773000 | USD | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
26648000 | USD | |
CY2020Q3 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.241 | |
CY2019Q3 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.271 | |
us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.254 | ||
us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.250 | ||
CY2020Q3 | supn |
Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
|
11100000 | USD |
CY2019Q4 | supn |
Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
|
11000000.0 | USD |
CY2020Q3 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
9528000 | USD |
CY2019Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
4582000 | USD |
CY2020Q3 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
17571000 | USD |
CY2019Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
11428000 | USD |
CY2020Q3 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
15366000 | USD |
CY2019Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
10618000 | USD |
CY2020Q3 | us-gaap |
Inventory Net
InventoryNet
|
42465000 | USD |
CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
26628000 | USD |
CY2020Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
31907000 | USD |
CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
29767000 | USD |
CY2020Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
14512000 | USD |
CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
12699000 | USD |
CY2020Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17395000 | USD |
CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17068000 | USD |
CY2020Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
700000 | USD |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1800000 | USD | |
CY2019Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
400000 | USD |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1100000 | USD | |
CY2020Q3 | us-gaap |
Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
|
1000000.0 | USD |
CY2020Q3 | us-gaap |
Goodwill Gross
GoodwillGross
|
89143000 | USD |
CY2019Q4 | us-gaap |
Goodwill Gross
GoodwillGross
|
0 | USD |
CY2020Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
28348000 | USD |
CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
18535000 | USD |
CY2020Q3 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
402265000 | USD |
CY2019Q4 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
24840000 | USD |
CY2020Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
6100000 | USD |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9800000 | USD | |
CY2019Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1300000 | USD |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
3900000 | USD | |
CY2020Q3 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
6264000 | USD |
CY2019Q4 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
13285000 | USD |
CY2020Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
14892000 | USD |
CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11223000 | USD |
CY2020Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2627000 | USD |
CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3936000 | USD |
CY2020Q3 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
14678000 | USD |
CY2019Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
0 | USD |
CY2020Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
17828000 | USD |
CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5861000 | USD |
CY2020Q3 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
56289000 | USD |
CY2019Q4 | us-gaap |
Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
|
34305000 | USD |
CY2020Q3 | supn |
Accrued Rebates
AccruedRebates
|
110543000 | USD |
CY2019Q4 | supn |
Accrued Rebates
AccruedRebates
|
88811000 | USD |
CY2020Q3 | supn |
Accrued Product Returns
AccruedProductReturns
|
26430000 | USD |
CY2019Q4 | supn |
Accrued Product Returns
AccruedProductReturns
|
18818000 | USD |
CY2020Q3 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
136973000 | USD |
CY2019Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
107629000 | USD |
CY2019Q3 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
4000000.0 | USD |
CY2020Q3 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
4945000 | USD |
CY2019Q3 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
4546000 | USD |
us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
14430000 | USD | |
us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
13518000 | USD | |
CY2020Q3 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
1143000 | USD |
CY2019Q3 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
1116000 | USD |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
3228000 | USD | |
us-gaap |
Interest Expense Other
InterestExpenseOther
|
3412000 | USD | |
CY2020Q3 | us-gaap |
Interest Expense
InterestExpense
|
6088000 | USD |
CY2019Q3 | us-gaap |
Interest Expense
InterestExpense
|
5662000 | USD |
us-gaap |
Interest Expense
InterestExpense
|
17658000 | USD | |
us-gaap |
Interest Expense
InterestExpense
|
16930000 | USD | |
CY2020Q3 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
4200000 | USD |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
12400000 | USD | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
11700000 | USD | |
CY2014Q3 | supn |
Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
|
30000000.0 | USD |